Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype

doi:10.3748/wjg.v20.i21.6400

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 21

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8863)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-1) series.

Item

Count

PDF

660

WORD

264

HTML

5947

Figures (1-6)

219

Tables (1-1)

167

Sum=7257

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

930

Download

676

Sum=1606

Jun 7, 2014 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (41)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 7, 2014; 20(21): 6400-6411
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6400

Full Size Figure Download Figure

Figure 6 Study design and outcomes. A: Patients were classified into two treatment regimens: standard treatment group (first- or second-line standard Japanese regimen) and tailored treatment group (based on clarithromycin-susceptibility); B: Eradication rates for the standard and tailored regimens for eradication of Helicobacter pylori; C: Eradication rates for the standard and tailored regimens among different CYP2C19 genotypes. CAM: Clarithromycin; PPI: Proton pump inhibitor; AMPC: Amoxicillin; MNZ: Metronidazole; RPZ: Rabeprazole.

Citation: Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol 2014; 20(21): 6400-6411
URL: https://www.wjgnet.com/1007-9327/full/v20/i21/6400.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i21.6400